Different biologics for biological-na ïve patients with psoriatic arthritis: a systematic review and network meta-analysis

Conclusion: In 2023, considering both efficacy and safety, IL-17Ai may be the better treatment option for biological-naïve patients with PsA requiring biological therapy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research